We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XImage: Vytronus is developing the only treatment option for atrial fibrillation that uses low-intensity collimated ultrasound (LICU). Photo: courtesy of PRNewswire / Vytronus, Inc.